TY - JOUR
T1 - Long term efficacy and assessment of tumor response of transarterial chemoembolization in neuroendocrine liver metastases
T2 - A 15‐year monocentric experience
AU - Touloupas, Caroline
AU - Faron, Matthieu
AU - Hadoux, Julien
AU - Deschamps, Frédéric
AU - Roux, Charles
AU - Ronot, Maxime
AU - Yevich, Steven
AU - Joskin, Julien
AU - Gelli, Maximiliano
AU - Barbé, Rémy
AU - Lamartina, Livia
AU - Tissot, Hubert
AU - Scoazec, Jean Yves
AU - Malka, David
AU - Ducreux, Michel
AU - Baudin, Eric
AU - de Baère, Thierry
AU - Tselikas, Lambros
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: transarterial chemoembolization (TACE) is an established treatment for neu-roendocrine tumor (NET) liver metastases. The aim was to evaluate the long‐term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival. Methods: this IRB-approved, single‐center, retrospective study evaluated all TACE procedures performed for NET liver metastases from 2003–2017 for imaging tumor response (RECIST and mRECIST), time to liver progression (TTLP), time to untreatable progression with TACE (TTUP), and overall survival (OS). Patient, tumor, and treatment characteristics were analyzed as prognostic factors. Survival curves according to the Kaplan–Meier method were compared by Log‐rank test. Tumor responses accord‐ ing to RECIST and mRECIST were correlated with OS. Results: 555 TACE procedures were performed in 202 NET patients (38% grade 1, 60% grade 2) with primary tumors originating from pan-creas, small bowel, and lung (39, 26, and 22% respectively). Median follow‐up was 8.2 years (90–139 months). Median TTLP and TTUP were 19.3 months (95%CI 16.3–22.3) and 26.2 months (95%CI 22.3– 33.1), respectively. Median OS was 5.3 years (95%CI 4.2–6.7), and was higher among mRECIST re-sponders (80.5 months; 95%CI 64.6–89.8) than in non‐responders (39.6 months; 95%CI = 32.8–60.2; p < 0.001). In multivariable analysis, age, tumor grade and liver involvement predicted worse OS, whereas administration of somatostatin analogs correlated with improved OS. Conclusion: TACE for NET liver metastases provides objective response and sustained local disease control rates. RE‐ CIST and mRECIST responses correlate with OS.
AB - Background: transarterial chemoembolization (TACE) is an established treatment for neu-roendocrine tumor (NET) liver metastases. The aim was to evaluate the long‐term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival. Methods: this IRB-approved, single‐center, retrospective study evaluated all TACE procedures performed for NET liver metastases from 2003–2017 for imaging tumor response (RECIST and mRECIST), time to liver progression (TTLP), time to untreatable progression with TACE (TTUP), and overall survival (OS). Patient, tumor, and treatment characteristics were analyzed as prognostic factors. Survival curves according to the Kaplan–Meier method were compared by Log‐rank test. Tumor responses accord‐ ing to RECIST and mRECIST were correlated with OS. Results: 555 TACE procedures were performed in 202 NET patients (38% grade 1, 60% grade 2) with primary tumors originating from pan-creas, small bowel, and lung (39, 26, and 22% respectively). Median follow‐up was 8.2 years (90–139 months). Median TTLP and TTUP were 19.3 months (95%CI 16.3–22.3) and 26.2 months (95%CI 22.3– 33.1), respectively. Median OS was 5.3 years (95%CI 4.2–6.7), and was higher among mRECIST re-sponders (80.5 months; 95%CI 64.6–89.8) than in non‐responders (39.6 months; 95%CI = 32.8–60.2; p < 0.001). In multivariable analysis, age, tumor grade and liver involvement predicted worse OS, whereas administration of somatostatin analogs correlated with improved OS. Conclusion: TACE for NET liver metastases provides objective response and sustained local disease control rates. RE‐ CIST and mRECIST responses correlate with OS.
KW - Chemoembolization
KW - Intra‐arterial therapies
KW - Liver metastases
KW - MRE‐ CIST
KW - Neuroendocrine neoplasms
KW - RECIST
UR - http://www.scopus.com/inward/record.url?scp=85117933864&partnerID=8YFLogxK
U2 - 10.3390/cancers13215366
DO - 10.3390/cancers13215366
M3 - Article
AN - SCOPUS:85117933864
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 21
M1 - 5366
ER -